G192 The Use of Faecal Calprotectin in Paediatric Inflammatory Bowel Disease
Identifieur interne : 000302 ( Main/Exploration ); précédent : 000301; suivant : 000303G192 The Use of Faecal Calprotectin in Paediatric Inflammatory Bowel Disease
Auteurs : Jr O Orman [Royaume-Uni] ; S. Hussey [Irlande (pays)] ; Rk Russell [Royaume-Uni]Source :
- Archives of Disease in Childhood [ 0003-9888 ] ; 2013-06.
Abstract
Aims To evaluate the use of faecal calprotectin (FC) in children with suspected inflammatory bowel disease (IBD) in the previous year, and to establish if the number of negative endoscopies had been minimised without missing any cases of IBD. To assess the use of FC in established paediatric IBD. To analyse the cost benefit of the test. Methods A retrospective analysis of FC measurements carried out between 1st October 2011 and 30th September 2012. FC measurements were obtained from the biochemistry department. Following a computerised search of the departmental records the presenting complaint, endoscopy result if applicable, diagnosis of IBD or alternative diagnosis, and follow-up or discharge were recorded for each patient. Patients were divided into those who were scoped based on their FC value and those who were not. Established IBD patients who had a FC test as part of their disease management were treated as a separate group. Results 36 patients (55%) were not scoped. All 36 had at least one symptom indicative of IBD. 25 of these had a FC value of <50µg/g. 4 of these patients had a FC result > 200µg/g. None of these patients have been diagnosed with IBD. 17 patients were scoped (26%). 3 of these patients were diagnosed with IBD. Median FC for the group that were not scoped was 30µg/g (interquartile range (IQR) 30–760µg/g), compared with 126µg/g (IQR 52 –1,590µg/g) in the group that were scoped. 8 patients with known IBD had a FC test when they became symptomatic and all FC values were consistent with GI inflammation. Overall, there was a 38% cost saving due to 44 unnecessary endoscopies being avoided. Conclusion FC is a valuable test for excluding IBD in patients who present with abdominal pain and diarrhoea. FC can confirm relapse in symptomatic patients known to have IBD. When the test is used in these ways patients avoid an invasive procedure and the hospital is saved the cost of the endoscopy. However, guidelines are required to ensure the correct and appropriate use of this relatively new test.
Url:
DOI: 10.1136/archdischild-2013-304107.204
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000095
- to stream Istex, to step Curation: 000065
- to stream Istex, to step Checkpoint: 000021
- to stream Main, to step Merge: 000303
- to stream Main, to step Curation: 000302
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">G192 The Use of Faecal Calprotectin in Paediatric Inflammatory Bowel Disease</title><author><name sortKey="O Orman, Jr" sort="O Orman, Jr" uniqKey="O Orman J" first="Jr" last="O Orman">Jr O Orman</name></author><author><name sortKey="Hussey, S" sort="Hussey, S" uniqKey="Hussey S" first="S" last="Hussey">S. Hussey</name></author><author><name sortKey="Russell, Rk" sort="Russell, Rk" uniqKey="Russell R" first="Rk" last="Russell">Rk Russell</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FD72FD034BE0DC375D542AB0322789FA28D5987A</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/archdischild-2013-304107.204</idno><idno type="url">https://api.istex.fr/document/FD72FD034BE0DC375D542AB0322789FA28D5987A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000095</idno><idno type="wicri:Area/Istex/Curation">000065</idno><idno type="wicri:Area/Istex/Checkpoint">000021</idno><idno type="wicri:doubleKey">0003-9888:2013:O Orman J:g:the:use</idno><idno type="wicri:Area/Main/Merge">000303</idno><idno type="wicri:Area/Main/Curation">000302</idno><idno type="wicri:Area/Main/Exploration">000302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">G192 The Use of Faecal Calprotectin in Paediatric Inflammatory Bowel Disease</title><author><name sortKey="O Orman, Jr" sort="O Orman, Jr" uniqKey="O Orman J" first="Jr" last="O Orman">Jr O Orman</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Medicine, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Hussey, S" sort="Hussey, S" uniqKey="Hussey S" first="S" last="Hussey">S. Hussey</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Paediatric Gastroenterology, Our Lady’s Children’s Hospital, Dublin</wicri:regionArea><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Russell, Rk" sort="Russell, Rk" uniqKey="Russell R" first="Rk" last="Russell">Rk Russell</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Archives of Disease in Childhood</title><title level="j" type="abbrev">Arch Dis Child</title><idno type="ISSN">0003-9888</idno><idno type="eISSN">1468-2044</idno><imprint><publisher>BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">98</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="A87">A87</biblScope></imprint><idno type="ISSN">0003-9888</idno></series><idno type="istex">FD72FD034BE0DC375D542AB0322789FA28D5987A</idno><idno type="DOI">10.1136/archdischild-2013-304107.204</idno><idno type="href">archdischild-98-A87-1.pdf</idno><idno type="ArticleID">archdischild-2013-304107.204</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-9888</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aims To evaluate the use of faecal calprotectin (FC) in children with suspected inflammatory bowel disease (IBD) in the previous year, and to establish if the number of negative endoscopies had been minimised without missing any cases of IBD. To assess the use of FC in established paediatric IBD. To analyse the cost benefit of the test. Methods A retrospective analysis of FC measurements carried out between 1st October 2011 and 30th September 2012. FC measurements were obtained from the biochemistry department. Following a computerised search of the departmental records the presenting complaint, endoscopy result if applicable, diagnosis of IBD or alternative diagnosis, and follow-up or discharge were recorded for each patient. Patients were divided into those who were scoped based on their FC value and those who were not. Established IBD patients who had a FC test as part of their disease management were treated as a separate group. Results 36 patients (55%) were not scoped. All 36 had at least one symptom indicative of IBD. 25 of these had a FC value of <50µg/g. 4 of these patients had a FC result > 200µg/g. None of these patients have been diagnosed with IBD. 17 patients were scoped (26%). 3 of these patients were diagnosed with IBD. Median FC for the group that were not scoped was 30µg/g (interquartile range (IQR) 30–760µg/g), compared with 126µg/g (IQR 52 –1,590µg/g) in the group that were scoped. 8 patients with known IBD had a FC test when they became symptomatic and all FC values were consistent with GI inflammation. Overall, there was a 38% cost saving due to 44 unnecessary endoscopies being avoided. Conclusion FC is a valuable test for excluding IBD in patients who present with abdominal pain and diarrhoea. FC can confirm relapse in symptomatic patients known to have IBD. When the test is used in these ways patients avoid an invasive procedure and the hospital is saved the cost of the endoscopy. However, guidelines are required to ensure the correct and appropriate use of this relatively new test.</div></front></TEI><affiliations><list><country><li>Irlande (pays)</li><li>Royaume-Uni</li></country><region><li>Écosse</li></region><settlement><li>Glasgow</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Royaume-Uni"><region name="Écosse"><name sortKey="O Orman, Jr" sort="O Orman, Jr" uniqKey="O Orman J" first="Jr" last="O Orman">Jr O Orman</name></region><name sortKey="Russell, Rk" sort="Russell, Rk" uniqKey="Russell R" first="Rk" last="Russell">Rk Russell</name></country><country name="Irlande (pays)"><noRegion><name sortKey="Hussey, S" sort="Hussey, S" uniqKey="Hussey S" first="S" last="Hussey">S. Hussey</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/MozartV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= MozartV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FD72FD034BE0DC375D542AB0322789FA28D5987A
|texte= G192 The Use of Faecal Calprotectin in Paediatric Inflammatory Bowel Disease
}}
| This area was generated with Dilib version V0.6.20. |  |